(S)-2-(1,3-Dioxoisoindolin-2-yl)pentanedioic acid, 95.0%, 25g

Methyl nicotinate, 95.0%, 1g

BAY 11-7082>98.0%(HPLC)(N)1g

(R)-5-isopropyl-2-(perfluorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium tetrafluoroborate, 97%, 100mg

n-pentano, mínimo 99 %, para síntesis, 100 ml, envase de vidrio

n-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide, 97%, 250mg

N,N-Bis(2-chloroethyl)propan-1-amine hydrochloride, 97%, 100mg

2-Phenyl-2-piperidin-2-ylacetamide hydrate, 97.0%, 5g

N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine dihydrochloride, 98%, 250mg

tert-Butyl 4-(2-chloro-4-fluorobenzylamino)piperidine-1-carboxylate, 1g

2,4,6-Tri([1,1'-biphenyl]-4-yl)-1,3,5-triazine, 97%, 1g

Mitoxantrone>95.0%(HPLC)200mg

SULFAQUINOXALINE SODIUM, 95%, 1g